Los Angeles, CA (PRWEB) February 26, 2007
The University of California at Los Angeles & SiliconMED announced today the launch of ProbeSetAnalyzer.com, a new web based tool aiming to help clinicians better visualize gene expression levels and how they relate to the overall survival of brain cancer patients.
The free tool, is the first of its kind allowing anyone to enter a gene description term or probe set id and instantly see if the gene they are looking for is a predictor of survival. With over 22,000 probe sets available on 164 patients, there is a tremendous amount of data available to all willing to ask questions. This service is primarily intended to allow brain cancer researchers to identify genes of interest for further study.
The tool was a collaborative effort between Dr. Timothy Cloughesy, UCLA Neuro-Oncology, Dr. Stanley F. Nelson, UCLA Department of Human Genetics and Michael Quinn, product developer of SiliconMED.
Unique to the Probe Set Analyzer is the ability to quickly compare multiple probes normally sharing the same gene description term, the integration of a statistical engine to calculate p-values based on Kaplan-Meier curves, and the ability to quickly screen results based on “Newly Diagnosed” or “Recurrent” tumor and/or by pathological diagnosis. “In reality there are over 1600 variables the probe set analyzer can screen against. In this initial release, we tried to keep the interface as simple as possible,” said Michael Quinn.
The current set of array and survival data comes from consented patients treated by UCLA’s Neuro-Oncology program. Array creation and normalization of gene expression data were performed by the Stanley F. Nelson Laboratory at UCLA. The current array contained tissue samples identified as “Newly” diagnosed or “Recurrent” primary Brain Tumor and samples were further categorized by Pathologic Diagnosis. 79.9% of the current samples had a diagnosis of Glioblastoma Multiforme (GBM), followed by Anaplastic As¬trocytoma (AA) 6.7% , Anaplastic Mixed Glioma (AMG) 6.7% and Anaplastic Oligodendroglioma (AO) 6.7%. “We are delighted to organize and provide this data back to the research community for the benefit of all cancer patients”, said Dr. Stanley F. Nelson, a human genetic researcher leading the genomic analysis of brain cancers. “Genomic experiments are expensive to perform. Even though the results are published, there is still substantial additional information that can only be unearthed through expert mining which this system greatly facilitates. We hope that this facilitates specific exploration of individual genes.”
“As a part of the UCLA Neuro-Oncology’s commitment to accelerate the process of new discovery through translational research projects, we decided we wanted to begin to share what we know about these samples in hope to stimulate feedback from the community,” said Dr, Timothy Cloughesy, director of the UCLA Neuro-Oncology Program. “We feel our translation research information system is leading the way. We currently have over 3000 consented patients in our system with detailed clinical information. 2100 of those patients have uncompressed DICOM imaging instantly available and 1600 of those patients have tissue resources available in our tissue bank ready for researchers who have legitimate research questions. It is truly a rich resource available to those willing to focus on curing this disease.”
About UCLA Neuro-Oncology
The UCLA Neuro-Oncology program provides a Multi-disciplinary approach to patients suffering from neuro-oncologic diseases such as primary malignant brain tumors, primary malignant spinal cord tumors, metastatic brain tumors, carcinomatous meningitis, epidural spinal cord compression, paraneoplastic disorders and neurologic complications of cancer and its treatment. This program utilizes experts in the fields of Neurology, Neuro-surgery, Medical Oncology, Radiation Oncology, Neuro-Pathology, Neuro-Imaging, Neuropsychiatry, Neuro-psychology, and social work to provide the most advanced and individualized care. This team of experts are leaders not only in defining state of the art care but are also intimately involved in the design of novel clinical trials including, antiangiogenesis agents, signal transduction inhibitors, novel radiation sensitizers, immune based therapies, gene therapies, biologic agents, blood brain barrier delivery systems. State of the art surgical facilities including an operative MRI suite allows for optimal tumor removal while ensuring maintenance of neurologic function.
Silicon Med North America Inc. is a privately held company with more then 10 years of experience building complex information systems. Our motivating principle — recognizing real-world inter-operability must exist between clinicians and researchers, while maintaining HIPAA security & patient confidentiality. We realize organizations are most efficient when each specialist has the data they need at the time of decision making.
Currently over 5000 patients worldwide are treated using SiliconMED’s Provider IQ decision support system. Provider IQ is the only intelligence architecture for Brain Cancer Research to unify Treatment Management, Diagnostic Imaging, Experimental Pathology, Gene Expression Analysis and “Patient Risk Assessment” tools that leverage 10 Years of Historical Treatment plans.
Michael Quinn (CEO)
# # #